Stock Track | Corcept Therapeutics Plunges 7.17% After-Hours on Mixed Q3 Results and Revenue Miss

Stock Track11-05

Shares of Corcept Therapeutics (NASDAQ: CORT) tumbled 7.17% in after-hours trading on Tuesday following the release of the company's third-quarter financial results. The biopharmaceutical firm, known for its cortisol-modulating therapeutics, reported a mixed bag of earnings that left investors concerned.

Corcept's Q3 earnings per share (EPS) came in at $0.16, surpassing the analyst consensus estimate of $0.14 by 18.52%. However, this represents a significant 60.98% decrease from the $0.41 per share reported in the same period last year. The company's revenue for the quarter stood at $207.638 million, falling short of analyst expectations of $218.526 million by 4.98%. Despite the miss, this figure still represents a 13.75% increase from the $182.546 million reported in the same quarter of the previous year.

Adding to investor concerns, Corcept provided a full-year revenue outlook of $800-850 million. This guidance, coupled with the revenue miss and the substantial year-over-year decline in EPS, likely contributed to the sharp after-hours sell-off. As the market digests these mixed results, investors will be closely watching how Corcept plans to address the revenue shortfall and improve profitability in the coming quarters.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131454549?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 05:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131454549","market":"us","top_or_hot":-1,"title":"Stock Track | Corcept Therapeutics Plunges 7.17% After-Hours on Mixed Q3 Results and Revenue Miss","media":"Stock Track","content":"<p>Shares of Corcept Therapeutics (NASDAQ: CORT) tumbled 7.17% in after-hours trading on Tuesday following the release of the company's third-quarter financial results. The biopharmaceutical firm, known for its cortisol-modulating therapeutics, reported a mixed bag of earnings that left investors concerned.</p>\n\n<p>Corcept's Q3 earnings per share (EPS) came in at $0.16, surpassing the analyst consensus estimate of $0.14 by 18.52%. However, this represents a significant 60.98% decrease from the $0.41 per share reported in the same period last year. The company's revenue for the quarter stood at $207.638 million, falling short of analyst expectations of $218.526 million by 4.98%. Despite the miss, this figure still represents a 13.75% increase from the $182.546 million reported in the same quarter of the previous year.</p>\n\n<p>Adding to investor concerns, Corcept provided a full-year revenue outlook of $800-850 million. This guidance, coupled with the revenue miss and the substantial year-over-year decline in EPS, likely contributed to the sharp after-hours sell-off. As the market digests these mixed results, investors will be closely watching how Corcept plans to address the revenue shortfall and improve profitability in the coming quarters.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Corcept Therapeutics Plunges 7.17% After-Hours on Mixed Q3 Results and Revenue Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Corcept Therapeutics Plunges 7.17% After-Hours on Mixed Q3 Results and Revenue Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 05:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Corcept Therapeutics (NASDAQ: CORT) tumbled 7.17% in after-hours trading on Tuesday following the release of the company's third-quarter financial results. The biopharmaceutical firm, known for its cortisol-modulating therapeutics, reported a mixed bag of earnings that left investors concerned.</p>\n\n<p>Corcept's Q3 earnings per share (EPS) came in at $0.16, surpassing the analyst consensus estimate of $0.14 by 18.52%. However, this represents a significant 60.98% decrease from the $0.41 per share reported in the same period last year. The company's revenue for the quarter stood at $207.638 million, falling short of analyst expectations of $218.526 million by 4.98%. Despite the miss, this figure still represents a 13.75% increase from the $182.546 million reported in the same quarter of the previous year.</p>\n\n<p>Adding to investor concerns, Corcept provided a full-year revenue outlook of $800-850 million. This guidance, coupled with the revenue miss and the substantial year-over-year decline in EPS, likely contributed to the sharp after-hours sell-off. As the market digests these mixed results, investors will be closely watching how Corcept plans to address the revenue shortfall and improve profitability in the coming quarters.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CORT","symbol_name":"Corcept医疗","start_time":0,"source_url":"","article_id":"1131454549","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131454549","pubTimestamp":1762292148,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Corcept Therapeutics (NASDAQ: CORT) tumbled 7.17% in after-hours trading on Tuesday following the release of the company's third-quarter financial results. The biopharmaceutical firm, known...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CORT":"Corcept医疗"},"translate_title":"个股追踪|Corcept Therapeutics盘后暴跌7.17%Q3业绩好坏参半营收未达预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1},"content_text":"Shares of Corcept Therapeutics (NASDAQ: CORT) tumbled 7.17% in after-hours trading on Tuesday following the release of the company's third-quarter financial results. The biopharmaceutical firm, known for its cortisol-modulating therapeutics, reported a mixed bag of earnings that left investors concerned.\nCorcept's Q3 earnings per share (EPS) came in at $0.16, surpassing the analyst consensus estimate of $0.14 by 18.52%. However, this represents a significant 60.98% decrease from the $0.41 per share reported in the same period last year. The company's revenue for the quarter stood at $207.638 million, falling short of analyst expectations of $218.526 million by 4.98%. Despite the miss, this figure still represents a 13.75% increase from the $182.546 million reported in the same quarter of the previous year.\nAdding to investor concerns, Corcept provided a full-year revenue outlook of $800-850 million. This guidance, coupled with the revenue miss and the substantial year-over-year decline in EPS, likely contributed to the sharp after-hours sell-off. As the market digests these mixed results, investors will be closely watching how Corcept plans to address the revenue shortfall and improve profitability in the coming quarters.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131454549","isCrawlerRequest":true}